Dr. David Paul Taggart
CABG, CABG!
Dr. David Paul Taggart (UK) is a Professor of Cardiovascular Surgery at the University of Oxford, renowned for his transformative contributions to Coronary Artery Bypass Grafting (CABG) and arterial revascularization. He served as the principal investigator of the ART (Arterial Revascularization) trial, published in NEJM in 2016, and has been involved in major studies like the EXCEL trial. With over 340 peer-reviewed papers, his research and leadership have significantly advanced cardiovascular surgery, improving surgical techniques and outcomes for coronary artery disease patients.
One vivid memory is of Dr. Taggart attending the TCTAP meeting for over two decades and engaging in debates with interventional cardiologists. Through trials like MAINCOPRE, PRECOMBAT, SYNTAX, BEST, and EXCEL, he consistently led discussions on the efficacy of PCI versus CABG for left main and multivessel disease. His sharp analysis and data-driven arguments were captivating, and I had the privilege of participating in a debate on left main disease, where he always emerged victorious. His invaluable contributions and dedication to TCTAP are deeply appreciated.
Dr. David Paul Taggart (UK) is a Professor of Cardiovascular Surgery at the University of Oxford, renowned for his transformative contributions to Coronary Artery Bypass Grafting (CABG) and arterial revascularization. He served as the principal investigator of the ART (Arterial Revascularization) trial, published in NEJM in 2016, and has been involved in major studies like the EXCEL trial. With over 340 peer-reviewed papers, his research and leadership have significantly advanced cardiovascular surgery, improving surgical techniques and outcomes for coronary artery disease patients.
One vivid memory is of Dr. Taggart attending the TCTAP meeting for over two decades and engaging in debates with interventional cardiologists. Through trials like MAINCOPRE, PRECOMBAT, SYNTAX, BEST, and EXCEL, he consistently led discussions on the efficacy of PCI versus CABG for left main and multivessel disease. His sharp analysis and data-driven arguments were captivating, and I had the privilege of participating in a debate on left main disease, where he always emerged victorious. His invaluable contributions and dedication to TCTAP are deeply appreciated.